Norethindrone

Norethindrone is a lipid of Sterol Lipids (ST) class. Norethindrone is associated with abnormalities such as Endometriosis, site unspecified, Wiskott-Aldrich Syndrome and Estrogenic effect. The involved functions are known as Hemorrhage, Phosphorylation, Apoptosis, DNA Repair and Cell Cycle. Norethindrone often locates in Blood, Back, Body tissue, Nucleolar and Human tissue. The associated genes with Norethindrone are MMP gene, NR3C1 gene and Genes, Reporter. The related lipids are Steroids, 4,17 beta-dihydroxy-4-androstene-3-one, 4-estren-3,17-diol and Estranes.

Cross Reference

Introduction

To understand associated biological information of Norethindrone, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Norethindrone?

Norethindrone is suspected in Endometriosis, site unspecified, Estrogenic effect and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Norethindrone

MeSH term MeSH ID Detail
Pancreatic Neoplasms D010190 77 associated lipids
Arteriosclerosis D001161 86 associated lipids
Body Weight D001835 333 associated lipids
Total 3

PubChem Associated disorders and diseases

What pathways are associated with Norethindrone

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Norethindrone?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Norethindrone?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Norethindrone?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Norethindrone?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Norethindrone?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Norethindrone

Download all related citations
Per page 10 20 50 100 | Total 3869
Authors Title Published Journal PubMed Link
Neven P et al. A multicentre randomised trial to compare uterine safety of raloxifene with a continuous combined hormone replacement therapy containing oestradiol and norethisterone acetate. 2003 BJOG pmid:12618160
Jirapinyo M et al. Effect of combined oral estrogen/progestogen preparation (Kliogest) on bone mineral density, plasma lipids and postmenopausal symptoms in HRT-naïve Thai women. 2003 Acta Obstet Gynecol Scand pmid:12911449
Li C et al. Low-dose hormone therapy and carbohydrate metabolism. 2003 Fertil. Steril. pmid:12620438
Boon J et al. Continuous intrauterine compared with cyclic oral progestin administration in perimenopausal HRT. 2003 Maturitas pmid:12963171
Davies P et al. Progestogens for menstrual migraine. 2003 J Br Menopause Soc pmid:14959722
Stanczyk FZ All progestins are not created equal. 2003 Steroids pmid:14667980
Ylikorkala O et al. Effects of hormone therapy and alendronate on C-reactive protein, E-selectin, and sex hormone-binding globulin in osteoporotic women. 2003 Fertil. Steril. pmid:12969695
Aussenac F et al. Cholesterol dynamics in membranes of raft composition: a molecular point of view from 2H and 31P solid-state NMR. 2003 Biochemistry pmid:12578350
Yamasaki K et al. Immature rat uterotrophic assay of 18 chemicals and Hershberger assay of 30 chemicals. 2003 Toxicology pmid:12504345
Conner P et al. Breast cell proliferation in postmenopausal women during HRT evaluated through fine needle aspiration cytology. 2003 Breast Cancer Res. Treat. pmid:12725416
Franke HR and Vermes I Differential effects of progestogens on breast cancer cell lines. 2003 Maturitas pmid:14670646
Althuis MD et al. Hormonal content and potency of oral contraceptives and breast cancer risk among young women. 2003 Br. J. Cancer pmid:12556959
Skarda J Bioassay of steroid hormone agonist and antagonist activities of anti-androgens on mammary gland, seminal vesicles and spleen of male mice. 2003 J Vet Med A Physiol Pathol Clin Med pmid:12948158
Yilmazer M et al. Hormone replacement therapy, C-reactive protein, and fibrinogen in healthy postmenopausal women. 2003 Maturitas pmid:14625121
Cengiz B et al. Effect of hormone replacement therapy on serum levels of tumor markers in healthy postmenopausal women. 2003 Maturitas pmid:14625127
Abrahamsen B et al. Effects of the natural and artificial menstrual cycle on the production of osteoprotegerin and the bone resorptive cytokines IL-1beta and IL-6. 2003 Calcif. Tissue Int. pmid:12384814
Boyd RA et al. The effect of food on the bioavailability of norethindrone and ethinyl estradiol from norethindrone acetate/ethinyl estradiol tablets intended for continuous hormone replacement therapy. 2003 J Clin Pharmacol pmid:12520628
Barth A et al. Influence of ethinyloestradiol propanolsulphonate on serum bile acids in healthy volunteers. 2003 Exp. Toxicol. Pathol. pmid:12877349
Comparative study of the effects of two once-a-month injectable contraceptives (Cyclofem and Mesigyna) and one oral contraceptive (Ortho-Novum 1/35) on coagulation and fibrinolysis. 2003 Contraception pmid:14561536
Görög S Chemical and analytical characterization of related organic impurities in drugs. 2003 Anal Bioanal Chem pmid:12937879
Martelli A et al. Species, sex and inter-individual differences in DNA repair induced by nine sex steroids in primary cultures of rat and human hepatocytes. 2003 Mutat. Res. pmid:12694747
Coyle D et al. Economic evaluation of norethisterone acetate/ethinylestradiol (FemHRT) for women with menopausal symptoms. 2003 Pharmacoeconomics pmid:12807367
Walker AE et al. PRIME--PRocess modelling in ImpleMEntation research: selecting a theoretical basis for interventions to change clinical practice. 2003 BMC Health Serv Res pmid:14683530
Strandberg TE et al. Differing effects of oral and transdermal hormone replacement therapy on cardiovascular risk factors in healthy postmenopausal women. 2003 Am. J. Cardiol. pmid:12860228
Nagaoka S et al. The des-gamma-carboxy prothrombin index is a new prognostic indicator for hepatocellular carcinoma. 2003 Cancer pmid:14669288
de Gooyer ME et al. Tibolone is not converted by human aromatase to 7alpha-methyl-17alpha-ethynylestradiol (7alpha-MEE): analyses with sensitive bioassays for estrogens and androgens and with LC-MSMS. 2003 Steroids pmid:12628686
Ellertson C et al. Modifying the Yuzpe regimen of emergency contraception: a multicenter randomized controlled trial. 2003 Obstet Gynecol pmid:12798518
Van Vliet HA et al. Biphasic versus monophasic oral contraceptives for contraception. 2003 Cochrane Database Syst Rev pmid:12804421
Van Vliet HA et al. Biphasic versus triphasic oral contraceptives for contraception. 2003 Cochrane Database Syst Rev pmid:12804457
Fenkci V et al. The short-term effects of different regimens of hormone replacement therapy on left ventricular structure and performance in healthy postmenopausal women. A prospective, controlled echocardiographic study. 2003 Gynecol. Obstet. Invest. pmid:12865592
Arabi A et al. Changes in body composition during post-menopausal hormone therapy: a 2 year prospective study. 2003 Hum. Reprod. pmid:12871894
Anderson RA et al. Evidence for tissue selectivity of the synthetic androgen 7 alpha-methyl-19-nortestosterone in hypogonadal men. 2003 J. Clin. Endocrinol. Metab. pmid:12788888
Gambacciani M et al. Effects of low-dose, continuous combined estradiol and noretisterone acetate on menopausal quality of life in early postmenopausal women. 2003 Maturitas pmid:12590012
Portman DJ et al. A randomized, double-blind, placebo-controlled, multicenter study that assessed the endometrial effects of norethindrone acetate plus ethinyl estradiol versus ethinyl estradiol alone. 2003 Am. J. Obstet. Gynecol. pmid:12592236
Simon JA et al. Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy. 2003 Am. J. Obstet. Gynecol. pmid:12548201
Gorgulu S et al. The effects of hormonal therapy on aortic stiffness and left ventricular diastolic function. 2003 Acta Cardiol pmid:12625488
Zouboulis CC and Piquero-Martin J Update and future of systemic acne treatment. 2003 Dermatology (Basel) pmid:12566804
Biglia N et al. Modification of serum IGF-I, IGFBPs and SHBG levels by different HRT regimens. 2003 Maturitas pmid:12927315
Doose DR et al. Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects. 2003 Epilepsia pmid:12681003
Cano A et al. The lipid and clinical effects of sequential transdermal estradiol and estradiol/norethisterone acetate in 674 women. 2003 Arch. Gynecol. Obstet. pmid:14504877
Hall SD et al. The interaction between St John's wort and an oral contraceptive. 2003 Clin. Pharmacol. Ther. pmid:14663455
McLeod LD et al. Evaluating minimal clinically important differences for the acne-specific quality of life questionnaire. 2003 Pharmacoeconomics pmid:14596626
McKenzie J et al. Metabolic, inflammatory and haemostatic effects of a low-dose continuous combined HRT in women with type 2 diabetes: potentially safer with respect to vascular risk? 2003 Clin. Endocrinol. (Oxf) pmid:14974908
Schindler AE et al. Classification and pharmacology of progestins. 2003 Maturitas pmid:14670641
Nugent AG et al. Modulation by progestogens of the effects of oestrogen on hepatic endocrine function in postmenopausal women. 2003 Clin. Endocrinol. (Oxf) pmid:14974909
Beksinska ME et al. Detection of raised FSH levels among older women using depomedroxyprogesterone acetate and norethisterone enanthate. 2003 Contraception pmid:14636937
de Visser SJ et al. Pharmacokinetic differences between Caucasian and Japanese subjects after single and multiple doses of a potential combined oral contraceptive (Org 30659 and EE). 2003 Contraception pmid:14561540
Stahlberg C et al. Hormone replacement therapy and risk of breast cancer: the role of progestins. 2003 Acta Obstet Gynecol Scand pmid:12790856
Christodoulakos GE et al. The effect of various regimens of hormone replacement therapy on mammographic breast density. 2003 Maturitas pmid:12787969
Kaleli B et al. Effects of low-dose 17-beta-estradiol plus norethisterone acetate and tibolone on fasting plasma homocysteine levels in postmenopausal women. 2003 Acta Obstet Gynecol Scand pmid:14616255